Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone for prevention of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage
jRCTs051230153Recruiting
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of hydrocortisone in subarachnoid hemorrhage (SAH) and cerebral vasospasm. Primary endpoint: Occurrence of symptomatic vasospasm within 14 days after subarachnoid hemorrhage. Started Feb 2024; status: recruiting.
02
Drugs
hydrocortisone
03
Conditions
subarachnoid hemorrhage (SAH)cerebral vasospasm
Beyond the preview
Go deeper on jRCTs051230153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230153.